PubMed ID: 38984111 Author(s): Sorenson CM, Belecky-Adams TL, Sheibani N. Editorial: Ocular fibrosis: molecular and cellular mechanisms and treatment modalities. Front Ophthalmol (Lausanne). 2024 Jan 25;4:1362601. doi: 10.3389/fopht.2024.1362601. eCollection 2024. No abstract available. PMID 38984111 …
All Posts
Dual sensory impairments in companion dogs: Prevalence and relationship to cognitive impairment.
PubMed ID: 39413072 Author(s): Hopper RG, Bromberg RB, Salzman MM, Peterson KD, Rogers C, Cameron S, Mowat FM. Dual sensory impairments in companion dogs: Prevalence and relationship to cognitive impairment. PLoS One. 2024 Oct 16;19(10):e0310299. …
In vivo scanning laser fundus and high-resolution OCT imaging of retinal ganglion cell injury in a non-human primate model with an activatable fluorescent-labeled TAT peptide probe.
PubMed ID: 39642160 Author(s): Qiu X, Gammon ST, Rasmussen C, Pisaneschi F, Kim CBY, Ver Hoeve J, Millward SW, Barnett EM, Nork TM, Kaufman PL, Piwnica-Worms D. In vivo scanning laser fundus and high-resolution OCT …
Shared signaling pathways and comprehensive therapeutic approaches among diabetes complications.
PubMed ID: 39845838 Author(s): Ebrahimi M, Ahmadieh H, Rezaei Kanavi M, Safi S, Alipour-Parsa S, Advani S, Sorenson CM, Sheibani N. Shared signaling pathways and comprehensive therapeutic approaches among diabetes complications. Front Med (Lausanne). 2025 …
Choroidal Mast Cells and Pathophysiology of Age-Related Macular Degeneration.
PubMed ID: 38201254 Author(s): Malih S, Song YS, Sorenson CM, Sheibani N. Choroidal Mast Cells and Pathophysiology of Age-Related Macular Degeneration. Cells. 2023 Dec 26;13(1):50. doi: 10.3390/cells13010050. PMID 38201254 Journal: Cells, Volume 13, Issue 1, …
New Ophthalmology Professorship Awarded to Support Veterans
Daniel Knoch, MD, a professor of Ophthalmology and Visual Sciences at the University of Wisconsin-Madison School of Medicine and Public Health, formally received the inaugural appointment to the Carl and Mary Ann Berg Family Professorship of Ophthalmology on December 15.
NEXPEDE-1
A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Phase 2/3 Study to Evaluate the Safety and Efficacy of NEXAGON (Lufepirsen Ophthalmic Gel) in Subjects with Persistent Corneal Epithelial Defects (NEXPEDE-1).
KOWA 303
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD).
KOWA 301
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD).